| Abstrakt: |
Cutaneo us vasculitis (CV) has a broad spectrum of etiologies, and drugs are one of the main culprits. With the increasing use of targeted therapies in medicine, especially in rheumatology and oncology, the number of CV cases reported due to these drugs has increased. Therefore, the recognition and treatment of CV associated with targeted agents have become more and more important. In the literature, anti-TNFs (n = 73, 59.5%), secukinumab (n = 7, 6%), rituximab (n = 5, 4%), tocilizumab (n = 1, 0.8%), ustekinumab (n = 8, 6.5%), abatacept (n = 3, 2.4%), Janus kinase inhibitors (n = 3, 2.4%), alemtuzumab (n = 3, 2.4%), and immune checkpoint inhibitors (n = 20, 16%) have been reported as responsible agents. However, our knowledge of the pathogenetic mechanisms is fairly limited, and the standardized management is yet to be established. Furthermore, though it is uncommon, this complication may pose a safety issue. In this manuscript, we reviewed the literature on CV with or without systemic involvement related to targeted agents. We also proposed the pathogenetic mechanisms of these adverse events. Thus, we aimed to make it easier for clinicians to manage similar cases by reviewing the diagnosis and treatment processes. Key Points • It should be kept in mind that targeted therapies can lead to CV with or without systemic signs, which sometimes withholds their uses. • Since targeted therapies are often used in the treatment of autoimmune and inflammatory diseases, CV associated with targeted therapies is difficult to recognize, and it is often mistakenly attributed to the underlying disease. • Although the pathogenesis of CV associated with targeted therapies is not fully understood, there are several proposed mechanisms. • Corticosteroids are the mainstay of treatment after discontinuation of the offending targeted agent. [ABSTRACT FROM AUTHOR] |
Full text from SpringerLink